Navigation Links
Lilly Announces New Vice President of Oncology Research
Date:3/10/2011

INDIANAPOLIS, March 10, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Greg Plowman, M.D., Ph.D., will lead Lilly's oncology research efforts as the vice president, oncology research and senior vice president of ImClone Systems research.

In this innovative new role created by Lilly and ImClone, Plowman will oversee the oncology research efforts of both Lilly and its subsidiary, ImClone. Plowman will be based at ImClone's research center at the Alexandria Center™ for Life Science New York City and will start on March 28, 2011.

He will report jointly to Jan Lundberg, Ph.D., executive vice president, science and technology, and president, Lilly Research Laboratories (LRL), and Bernhard Ehmer, M.D., president of ImClone.

Oncology Research at Lilly, ImClone

"Oncology represents a major area of unmet medical need and rapidly advancing science is driving us to discover new treatments with better efficacy to prolong the survival of the patients we serve," said Lundberg. "The introduction of a new oncology research leader across Lilly and ImClone will ensure the pursuit of the right mechanisms, therapeutic agents and tailoring strategies across our oncology business."

"Greg's position is unique and his experience makes him an ideal choice for this new position," added Lundberg. "We believe it is one of the most exciting leadership positions in the industry given the breadth of our preclinical pipeline in both small and large molecules and the close working relationship with our clinical development group that tailors our medicines for patient needs."

Lilly acquired ImClone in 2008, broadening the Lilly Oncology portfolio and strengthening its oncology pipeline and biotech capabilities.  The company now has one of the largest clinical-stage pipelines of potential cancer medicines in the industry with more than 30 molecules.

About Greg Plowman

"Greg has a strong industry track record with experience in both biotech and big pharma," said Ehmer. "His leadership style and breadth of experience will help ensure a synergistic approach to our oncology pipeline efforts while preserving the innovative cultures of Lilly and ImClone for the benefit of the patients we serve.  This is critical for a collaboration of the size, scope and importance of the Lilly / ImClone partnership."

Prior to accepting this position, Plowman served as a senior director in research for six years at Genentech, a member of the Roche Group.  He directed research efforts in anti-angiogenesis (attempting to block the formation of blood vessels that supply nutrients and oxygen that encourage cancerous tumor growth), biomedical imaging, and tumor biology and was responsible for building a pipeline of innovative agents for treatment of cancer and ocular disease.

He has 25 years of experience in cancer research including leadership roles at four biotechs (Oncogen, Sugen, Exelixis, and Genentech) that became part of three pharmaceutical companies (Bristol-Myers Squibb, Pharmacia, and Roche).

Plowman received a bachelor's of arts in biology and chemistry from Whitman College, Walla Walla, Washington and earned his M.D. and Ph.D. from the University of Washington in Seattle.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

C-LLY

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/26/2016)... N.J. (PRWEB) , ... June 27, 2016 , ... Quality ... sources, yet in many ways they remain in the eye of the beholder, according ... (EBO), a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
Breaking Medicine News(10 mins):